8-K: Alzamend Neuro Amends Bylaws and Establishes Series C Convertible Preferred Stock

Alzamend Neuro updates its bylaws to reduce the quorum requirement for stockholder meetings and establishes a new Series C Convertible Preferred Stock.

Summary

• Alzamend Neuro, Inc. amended its bylaws on February 28, 2025, to decrease the quorum requirement for stockholder meetings.
• The quorum was reduced from a majority to 35% of the outstanding capital stock entitled to vote.
• On the same day, the company filed a Certificate of Designation to establish the Series C Convertible Preferred Stock.
• The company also entered into a Securities Purchase & Exchange Agreement with a sophisticated investor to exchange Series A Convertible Preferred Stock for Series C Preferred Stock and sell up to 500 shares of Series C Preferred Stock.

Sentiment

Score: 6

Explanation: The announcement is neutral, detailing routine corporate actions. The establishment of Series C Preferred Stock could be seen as slightly positive, indicating potential financing opportunities.

Positives

• The reduced quorum requirement may make it easier to conduct stockholder meetings.
• The establishment of Series C Preferred Stock could provide the company with additional financial flexibility.

Future Outlook

The document does not contain specific forward-looking statements beyond the transactions described.

Industry Context

Companies often adjust their bylaws and create new classes of stock to manage corporate governance and financing needs.

Corporate Governance

Stakeholder Impact

• Shareholders may be affected by the change in quorum requirements and the issuance of Series C Preferred Stock.
• The issuance of Series C Preferred Stock could impact the value and voting power of existing shares.

Key Dates